GlobeNewswire - Initial Public Offerings Contains the last 20 releases uuid:8f3c45ed-7282-4d04-a5a7-dd6d43c0ca7f;id=11703 2021-02-05T17:16:54Z newsdesk@globenewswire.com (NewsDesk) http://www.10gbhost.com/LegacyRss?Length=4 newsdesk@globenewswire.com http://www.10gbhost.com/news-release/2021/02/05/2170864/0/en/The-Music-Acquisition-Corporation-Announces-Closing-of-230-Million-Initial-Public-Offering.html The Music Acquisition Corporation Announces Closing of $230 Million Initial Public Offering 2021-02-05T17:16:54Z 2021-02-06T08:03:46Z New York, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The Music Acquisition Corporation (the “Company”) today announced the closing of its initial public offering of 23,000,000 units, which includes the 3,000,000 units sold pursuant to the exercise of the underwriters’ over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units are listed on the New York Stock Exchange (the “NYSE”) and commenced trading under the ticker symbol “TMAC.U” on February 3, 2021. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NYSE under the symbols “TMAC” and “TMAC WS,” respectively.

]]>
2170864 en GlobeNewswire Inc. Music Acquisition Corp Fri, 05 Feb 2021 17:17 GMT Press releases Company Announcement Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170844/0/en/Bright-Minds-Biosciences-Announces-Listing-on-Canadian-Stock-Exchange.html Bright Minds Biosciences Announces Listing on Canadian Stock Exchange 2021-02-05T16:30:00Z 2021-02-06T08:03:46Z VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced that the Company’s common shares (the “Shares”) are expected to commence trading on the Canadian Securities Exchange (the “CSE”) on Monday, February 8, 2021, under the ticker symbol “DRUG.”

]]>
2170844 en GlobeNewswire Inc. Bright Minds Biosciences Fri, 05 Feb 2021 16:30 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170837/0/en/TELUS-International-announces-closing-of-IPO-and-the-exercise-of-the-underwriters-over-allotment-option.html TELUS International announces closing of IPO and the exercise of the underwriters’ over-allotment option 2021-02-05T16:11:04Z 2021-02-06T08:03:46Z VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TELUS Corporation (TSX: T; NYSE: TU) (TELUS) and its subsidiary, TELUS International (Cda) Inc. (TSX and NYSE: TIXT) (TELUS International), today announced the closing of the upsized TELUS International initial public offering (IPO) of 42.55 million subordinate voting shares at a price of US$25.00 per share, which includes 5.55 million subordinate voting shares purchased upon the full exercise of the underwriters’ over-allotment option to purchase additional subordinate voting shares from TELUS and Baring Private Equity Asia (Baring), the selling shareholders.

]]>
2170837 en GlobeNewswire Inc. TELUS Communications Inc Fri, 05 Feb 2021 16:11 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170837/0/fr/TELUS-International-annonce-la-cl%C3%B4ture-du-premier-appel-public-%C3%A0-l-%C3%A9pargne-et-l-exercice-de-l-option-d-attribution-exc%C3%A9dentaire-des-preneurs-fermes.html TELUS International annonce la cl?ture du premier appel public à l’épargne et l’exercice de l’option d’attribution excédentaire des preneurs fermes 2021-02-05T16:11:04Z 2021-02-06T08:03:46Z VANCOUVER, Colombie-Britannique, 05 févr. 2021 (GLOBE NEWSWIRE) -- TELUS Corporation (TSX?: T; NYSE?: TU) (TELUS) et sa filiale, TELUS International (Canada) inc. (TSX et NYSE?: TIXT) (TELUS International), ont annoncé aujourd’hui la cl?ture du premier appel public à l’épargne majoré de TELUS International de 42,55?millions d’actions à droit de vote subalterne au prix de 25,00?$?US par action. Ce premier appel public à l’épargne comprenait 5,55?millions d’actions à droit de vote subalterne achetées par les preneurs fermes, qui ont exercé pleinement leur option d’attribution excédentaire d’acheter des actions à droit de vote subalterne supplémentaires de TELUS et de Baring Private Equity Asia (Baring), les actionnaires revendeurs.

]]>
2170837 fr GlobeNewswire Inc. TELUS Communications Inc Fri, 05 Feb 2021 16:11 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170706/0/en/Angion-Biomedica-Corp-Announces-Pricing-of-Initial-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement 2021-02-05T13:30:00Z 2021-02-06T08:03:46Z UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

]]>
2170706 en GlobeNewswire Inc. Angion Biomedica Corp. Fri, 05 Feb 2021 13:30 GMT Initial Public Offerings Stock Market News Changes in company's own shares IPO Initial Public Offering San Francisco Boston New York kidney lung transplant
http://www.10gbhost.com/news-release/2021/02/05/2170590/0/en/Vor-Biopharma-Announces-Pricing-of-Initial-Public-Offering.html Vor Biopharma Announces Pricing of Initial Public Offering 2021-02-05T11:33:56Z 2021-02-06T08:03:46Z CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately $176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

]]>
2170590 en GlobeNewswire Inc. Vor Biopharma Fri, 05 Feb 2021 11:34 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170417/0/en/Bolt-Biotherapeutics-Prices-Upsized-Initial-Public-Offering.html Bolt Biotherapeutics Prices Upsized Initial Public Offering 2021-02-05T03:34:45Z 2021-02-06T08:03:46Z REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00 per share. In addition, Bolt has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol "BOLT" on February 5, 2021.

]]>
2170417 en GlobeNewswire Inc. Bolt Biotherapeutics, Inc. Fri, 05 Feb 2021 03:34 GMT Initial Public Offerings Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170413/0/en/JOFF-Fintech-Acquisition-Corp-Announces-Pricing-of-upsized-360-000-000-Initial-Public-Offering.html JOFF Fintech Acquisition Corp. Announces Pricing of upsized $360,000,000 Initial Public Offering 2021-02-05T03:01:30Z 2021-02-06T08:03:46Z New York, NY, Feb. 04, 2021 (GLOBE NEWSWIRE) -- JOFF Fintech Acquisition Corp. (the “Company”) today announced the pricing of its upsized initial public offering of 36,000,000 units at?$10.00?per unit. The units will be listed on the Nasdaq Stock Market and trade under the ticker symbol “JOFFU” beginning?Friday, February 5, 2021.

]]>
2170413 en GlobeNewswire Inc. JOFF Fintech Acquisition Corp Fri, 05 Feb 2021 03:01 GMT Press releases Mergers and Acquisitions Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170403/0/en/Pharvaris-Announces-Pricing-of-Upsized-Initial-Public-Offering.html Pharvaris Announces Pricing of Upsized Initial Public Offering 2021-02-05T01:08:32Z 2021-02-06T08:03:46Z ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2021 under the symbol "PHVS."

]]>
2170403 en GlobeNewswire Inc. Pharvaris N.V. Fri, 05 Feb 2021 01:08 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170402/0/en/Thunder-Bridge-Capital-Partners-III-Inc-Announces-Pricing-of-Upsized-360-000-000-Initial-Public-Offering.html Thunder Bridge Capital Partners III Inc. Announces Pricing of Upsized $360,000,000 Initial Public Offering 2021-02-05T01:06:31Z 2021-02-06T08:03:46Z New York, NY , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Thunder Bridge Capital Partners III Inc. (the “Company”) announced today that it priced its upsized initial public offering of 36,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Friday, February 5, 2021, under the ticker symbol “TBCPU”. Each unit consists of one of the Company’s shares of Class A common stock and one-fifth of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. ?Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “TBCP” and “TBCPW,” respectively.

]]>
2170402 en GlobeNewswire Inc. Thunder Bridge Capital Partners III Inc. Fri, 05 Feb 2021 01:06 GMT Initial Public Offerings Company Announcement Exchange announcement Exchange News Press releases
http://www.10gbhost.com/news-release/2021/02/04/2170395/0/en/Terns-Pharmaceuticals-Inc-Announces-Pricing-of-Upsized-Initial-Public-Offering-of-Common-Stock.html Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock 2021-02-04T23:54:05Z 2021-02-06T08:03:46Z FOSTER CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share, for gross proceeds of $127.5 million, before the underwriting discounts and commissions. All of the shares of common stock are being offered by Terns. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Terns’ common stock has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “TERN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to customary closing conditions.

]]>
2170395 en GlobeNewswire Inc. Terns Pharmaceuticals, Inc. Thu, 04 Feb 2021 23:54 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/04/2170389/0/en/Quantum-FinTech-Acquisition-Corporation-Announces-Pricing-of-Upsized-175-Million-Initial-Public-Offering.html Quantum FinTech Acquisition Corporation Announces Pricing of Upsized $175 Million Initial Public Offering 2021-02-04T23:16:41Z 2021-02-06T08:03:46Z Tampa, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Quantum FinTech Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 17,500,000 units at $10.00 per unit. The units are expected to trade on the New York Stock Exchange (“NYSE”) under the ticker symbol “QFTA.U” beginning February 5, 2021. Each unit consists of one share of common stock and one redeemable warrant, with each warrant entitling the holder thereof to purchase one half-share of common stock at a price of $11.50 per full share. Once the securities comprising the units begin separate trading, the shares of common stock and redeemable warrants, are expected to be listed on the NYSE under the symbols “QFTA” and “QFTA WS,” respectively.

]]>
2170389 en GlobeNewswire Inc. Quantum FinTech Acquisition Corp Thu, 04 Feb 2021 23:17 GMT Mergers and Acquisitions Press releases Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/04/2170352/0/en/Evaxion-Biotech-Announces-Pricing-of-Initial-Public-Offering.html Evaxion Biotech Announces Pricing of Initial Public Offering 2021-02-04T21:16:51Z 2021-02-06T08:03:46Z COPENHAGEN, Denmark, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (“Evaxion”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, today announced the pricing of its initial public offering of 3,000,000 American Depositary Shares (“ADSs”), at a public offering price of $10 per ADS, with each such ADS representing one ordinary share, DKK 1 nominal value per share, of Evaxion (“Ordinary Shares”). The gross proceeds from the offering are expected to be approximately $30 million before deducting underwriting fees and commissions and other offering expenses. Evaxion has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 450,000 ADSs at the initial public offering price.

]]>
2170352 en GlobeNewswire Inc. Evaxion Biotech Thu, 04 Feb 2021 21:17 GMT Health Initial Public Offerings Stock Market News
http://www.10gbhost.com/news-release/2021/02/04/2170332/0/en/Oncocyte-Announces-Proposed-Public-Offering-of-Common-Stock.html Oncocyte Announces Proposed Public Offering of Common Stock 2021-02-04T21:05:00Z 2021-02-06T08:03:46Z IRVINE, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has commenced an underwritten public offering of its common stock. The Company intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by the Company.

]]>
2170332 en GlobeNewswire Inc. Oncocyte Corporation Thu, 04 Feb 2021 21:06 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/04/2169508/0/en/Atlas-Crest-Investment-Corp-II-Announces-Pricing-of-Upsized-300-Million-Initial-Public-Offering.html Atlas Crest Investment Corp. II Announces Pricing of Upsized $300 Million Initial Public Offering 2021-02-04T02:52:33Z 2021-02-06T08:03:46Z New York, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atlas Crest Investment Corp. II (NYSE: ACII.U, the "Company") announced today that it priced its upsized initial public offering of 30,000,000 units at a price to the public of $10.00 per unit. The units are expected to commence trading on February 4, 2021 on The New York Stock Exchange (the “NYSE”) under the ticker symbol "ACII.U". Each unit consists of one share of Class A common stock and one-fourth of one warrant, each whole warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be traded on the NYSE under the symbols "ACII" and "ACII.WS," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The offering is expected to close on February 8, 2021, subject to customary closing conditions.

]]>
2169508 en GlobeNewswire Inc. Atlas Crest Investment Corp. II Thu, 04 Feb 2021 02:53 GMT Press releases Company Announcement Initial Public Offerings Exchange announcement
http://www.10gbhost.com/news-release/2021/02/04/2169502/0/en/Sensei-Biotherapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering 2021-02-04T01:44:20Z 2021-02-06T08:03:46Z BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol “SNSE.” In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on February 8, 2021 subject to the satisfaction of customary closing conditions.

]]>
2169502 en GlobeNewswire Inc. Sensei Biotherapeutics Thu, 04 Feb 2021 01:44 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/04/2169500/0/en/Landos-Biopharma-Announces-Pricing-of-Initial-Public-Offering.html Landos Biopharma Announces Pricing of Initial Public Offering 2021-02-04T01:13:55Z 2021-02-06T08:03:46Z BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

]]>
2169500 en GlobeNewswire Inc. Landos Biopharma, Inc. Thu, 04 Feb 2021 01:13 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/04/2169499/0/en/Atotech-Prices-Initial-Public-Offering.html Atotech Prices Initial Public Offering 2021-02-04T01:11:17Z 2021-02-06T08:03:46Z BERLIN, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atotech Limited (“Atotech”), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, has priced its initial public offering of 29,268,000 of its common shares at $17.00 per share. The shares are expected to begin trading on Thursday, February 4, 2021 on the New York Stock Exchange under the ticker symbol “ATC,” and the offering is expected to close on February 8, 2021, subject to customary closing conditions. The underwriters of the offering will also have a 30-day option to purchase up to an additional 4,390,200 common shares from certain affiliates of The Carlyle Group Inc. (the “selling shareholders”).

]]>
2169499 en GlobeNewswire Inc. Atotech Thu, 04 Feb 2021 01:11 GMT Initial Public Offerings atotech IPO chemicalindustry specialtychemicals nyse pricing
http://www.10gbhost.com/news-release/2021/02/03/2169431/0/en/Astrea-Acquisition-Corp-Announces-Pricing-of-150-000-000-Initial-Public-Offering.html Astrea Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering 2021-02-03T21:31:58Z 2021-02-06T08:03:46Z New York, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Astrea Acquisition Corp. (NASDAQ:?ASAXU)?(the “Company”)?announced that it priced its initial public offering of 15,000,000 units at $10.00 per unit.? The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “ASAXU” beginning tomorrow, February 4, 2021.? Each unit consists of one?share of common stock and one-half of one?warrant to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. Once the securities comprising the units begin separate trading, the common stock and warrants are expected to be listed on Nasdaq under the symbols “ASAX” and “ASAXW,” respectively.

]]>
2169431 en GlobeNewswire Inc. Astrea Acquisition Corp. Wed, 03 Feb 2021 21:32 GMT Company Announcement Initial Public Offerings Exchange announcement Press releases
http://www.10gbhost.com/news-release/2021/02/03/2168895/0/en/Apria-Announces-Launch-of-Initial-Public-Offering.html Apria Announces Launch of Initial Public Offering 2021-02-03T11:25:44Z 2021-02-06T08:03:46Z INDIANAPOLIS, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) announced today the launch of its initial public offering of 7,500,000 shares of its common stock to be sold by certain of its stockholders. The initial public offering price is currently expected to be between $19.00 to $21.00 per share. The selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock. Apria intends to list its shares of common stock on the Nasdaq Global Select Market under the symbol “APR.”

]]>
2168895 en GlobeNewswire Inc. Apria, Inc. Wed, 03 Feb 2021 11:26 GMT Initial Public Offerings
亚洲精品私拍国产在线播放_亚洲综合区图片小说区_亚洲日本欧美日韩高观看